Category survey

Vascular Dysfunction in Cerebral Amyloid Angiopathy

Vascular Dysfunction in Cerebral Amyloid Angiopathy Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Brain Imaging, APOE & the Preclinical Course of Alzheimers Disease

Brain Imaging, APOE & the Preclinical Course of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Molecular and structural imaging in atypical Alzheimers disease: a longitudinal study

Molecular and structural imaging in atypical Alzheimers disease: a longitudinal study Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Early-Onset Alzheimers Disease Phenotypes: Neuropsychology and Neural Networks

Early-Onset Alzheimers Disease Phenotypes: Neuropsychology and Neural Networks Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Unified high performance analysis of imaging biomarkers for Alzheimers disease

Unified high performance analysis of imaging biomarkers for Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Longitudinal Cognitive ERP studies: Advancement for AD Clinical Trials

Longitudinal Cognitive ERP studies: Advancement for AD Clinical Trials Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Quantifying Brain Abnormality by Multimodality Neuroimage Analysis

Quantifying Brain Abnormality by Multimodality Neuroimage Analysis Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

In vivo characterization of the PET pharmacokinetic properties of T807 in humans

In vivo characterization of the PET pharmacokinetic properties of T807 in humans Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimers Disease

Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

TrkB Receptor PET Tracer Development

TrkB Receptor PET Tracer Development Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Biomarkers of Alzheimers Disease in Adults with Down Syndrome

Biomarkers of Alzheimers Disease in Adults with Down Syndrome Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimers Disease

Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Tau, amyloid, & white matter burden interact to impact brain networks in preclinical Alzheimers disease

Tau, amyloid, & white matter burden interact to impact brain networks in preclinical Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Antecedent Biomarker Changes in AD: Ordering, Stages, and Implications for Trials

Antecedent Biomarker Changes in AD: Ordering, Stages, and Implications for Trials Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimers Disease Clinical Trials

A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimers Disease Clinical Trials Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

The ARIC-PET Amyloid Imaging Study

The ARIC-PET Amyloid Imaging Study Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

The Longitudinal Course OF Imaging Biomarkers in People At RISK of AD

The Longitudinal Course OF Imaging Biomarkers in People At RISK of AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Vitamins D and K and Neuropathologically-Defined Alzheimer and Other Dementias in Older Persons

Vitamins D and K and Neuropathologically-Defined Alzheimer and Other Dementias in Older Persons Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Cognitive resilience to Alzheimer neuropathologic changes in the Honolulu-Asia Aging Study and the Nun Study

Cognitive resilience to Alzheimer neuropathologic changes in the Honolulu-Asia Aging Study and the Nun Study Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Neuropathologic-Epidemiological Study of Metallomics and Alzheimers Disease

Neuropathologic-Epidemiological Study of Metallomics and Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Alzheimers Disease & Related Dementias: Geography, Environments, and Mechanisms

Alzheimers Disease & Related Dementias: Geography, Environments, and Mechanisms Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

The Macrovascular and Microvascular Contributions to Alzheimers Disease: MESA VASCAD

The Macrovascular and Microvascular Contributions to Alzheimers Disease: MESA VASCAD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Offpsring Study of Mechanisms for Racial in Alzheimers Disease

Offpsring Study of Mechanisms for Racial in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

The Role of Intracranial Atherosclerosis in the Development of Alzheimers Disease

The Role of Intracranial Atherosclerosis in the Development of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Diabetes Status and Brain Amyloid in Middle Aged Hispanics

Diabetes Status and Brain Amyloid in Middle Aged Hispanics Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Plasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart Study

Plasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart Study Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

White Matter Hyperintentisities in Aging and Dementia

White Matter Hyperintentisities in Aging and Dementia Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Plasma beta-amyloid in long lived families: genetics and risk of AD

Plasma beta-amyloid in long lived families: genetics and risk of AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Healthy Aging and Senile Dementia

Healthy Aging and Senile Dementia Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Multi-Source Sparse Learning to Identify MCI and Predict Decline

Multi-Source Sparse Learning to Identify MCI and Predict Decline Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration

Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Disentangling the contribution of tau to aging and AD

Disentangling the contribution of tau to aging and AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Wisconsin Registry for Alzheimers Prevention: Biomarkers for Preclinical AD

Wisconsin Registry for Alzheimers Prevention: Biomarkers for Preclinical AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Validating the New Criteria for Preclinical Alzheimers disease

Validating the New Criteria for Preclinical Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

The Four Repeat Tauopathy Neuroimaging Initiative

The Four Repeat Tauopathy Neuroimaging Initiative Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Brain Imaging, APOE & the Preclinical Course of Alzheimers Disease

Brain Imaging, APOE & the Preclinical Course of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

White matter degeneration: biomarkers in preclinical Alzheimers Disease

White matter degeneration: biomarkers in preclinical Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Stress Mental Disorders Accelerated Aging and Dementia a 35 year Cohort Study

Stress Mental Disorders Accelerated Aging and Dementia a 35 year Cohort Study Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Role of midlife cardiovascular disease on Alzheimers Pathology and cerebrovascular reactivity in the young-old.

Role of midlife cardiovascular disease on Alzheimers Pathology and cerebrovascular reactivity in the young-old. Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Alzheimer neuroimaging-biomarkers in pre-clinical cognitive decline from a population-based study

Alzheimer neuroimaging-biomarkers in pre-clinical cognitive decline from a population-based study Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

MRI, Genetics & Cognitive Precursors of AD and Dementia

MRI, Genetics & Cognitive Precursors of AD and Dementia Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Alzheimers Disease Genetics Consortium

Alzheimers Disease Genetics Consortium Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Clinical, Imaging, and Pathological Studies in the Oldest Old: The 90+ Study

Clinical, Imaging, and Pathological Studies in the Oldest Old: The 90+ Study Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Racial Differences in Late-Life Cognitive decline and risk of Alzheimers Disease

Racial Differences in Late-Life Cognitive decline and risk of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Genes, environments, interactions, and cognitive decline in the HRS

Genes, environments, interactions, and cognitive decline in the HRS Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Epidemiologic Study of Decision Making in Preclinical Alzheimers Disease

Epidemiologic Study of Decision Making in Preclinical Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Sequence-based Discovery of AD Risk & Protective Alleles

Sequence-based Discovery of AD Risk & Protective Alleles Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample

CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Sequence-based Discovery of AD Risk & Protective Alleles

Sequence-based Discovery of AD Risk & Protective Alleles Investments > €500k United States of America Alzheimer’s disease & other dementias 2016

Modifier Genes that Influence Age at Onset or Protect Against Development of Alzheimers Disease (AD)

Modifier Genes that Influence Age at Onset or Protect Against Development of Alzheimers Disease (AD) Investments > €500k United States of America Alzheimer’s disease & other dementias 2016